Lukas Scheibler - Feb 10, 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Signature
/s/ David Watson, attorney-in-fact for Lukas Scheibler
Stock symbol
APLS
Transactions as of
Feb 10, 2022
Transactions value $
-$393,447
Form type
4
Date filed
2/14/2022, 03:15 PM
Previous filing
Feb 10, 2022
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction APLS Common Stock Tax liability -$31.9K -678 -1.26% $47.12 53.2K Feb 10, 2022 Direct F1
transaction APLS Common Stock Options Exercise $139K +10K +18.8% $13.85 63.2K Feb 10, 2022 Direct F2
transaction APLS Common Stock Sale -$500K -10K -15.83% $50.00 53.2K Feb 10, 2022 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction APLS Stock Option (Right to Buy) Options Exercise $0 -10K -13.33% $0.00 65K Feb 10, 2022 Common Stock 10K $13.85 Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This represents shares used to cover tax withholding on a Restricted Stock Unit release.
F2 This is a scheduled exercise from 10B5-1 trading plan.
F3 This is a scheduled sale from 10B5-1 trading plan.
F4 This represents a stock option grant made on 02/08/2019 that vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to the satisfaction of a specified performance condition and continued service.